Publikationen 2017

Prof. Dr. med. Markus Essler

 

1. Predictors of overall survival in metastatic castration-resistant prostate cancer patients receiving [177Lu]Lu-PSMA-617 radioligand therapy. Ahmadzadehfar H, Schlolaut S, Fimmers R, Yordanova A, Hirzebruch S, Schlenkhoff C, Gaertner FC, Awang ZH, Hauser S, Essler M.
Oncotarget. 2017 Oct 7;8(61):103108-103116. doi: 10.18632/oncotarget.21600. eCollection 2017

 

 

2. Cardiovascular magnetic resonance imaging and clinical performance of somatostatin receptor positron emission tomography in cardiac sarcoidosis.
Pizarro C, Kluenker F, Dabir D, Thomas D, Gaertner FC, Essler M, Grohé C, Nickenig G, Skowasch D.

 

3. Diagnostic accuracy of [99mTc]Tc-Sestamibi in the assessment of thyroid nodules.
Yordanova A, Mahjoob S, Lingohr P, Kalff J, Türler A, Palmedo H, Biersack HJ, Kristiansen G, Farahati J, Essler M, Ahmadzadehfar H.
Oncotarget. 2017 Oct 17;8(55):94681-94691. doi: 10.18632/oncotarget.21866. eCollection 2017 Nov 7.

 

 

4. Clinical Translation and First In-Human Use of [44Sc]Sc-PSMA-617 for PET Imaging of Metastasized Castrate-Resistant Prostate Cancer.
Eppard E, de la Fuente A, Benešová M, Khawar A, Bundschuh RA, Gärtner FC, Kreppel B, Kopka K, Essler M, Rösch F.
Theranostics. 2017 Sep 26;7(18):4359-4369. doi: 10.7150/thno.20586. eCollection 2017.

 

 

5. Delayed response after repeated 177Lu-PSMA-617 radioligand therapy in patients with metastatic castration resistant prostate cancer.
Rahbar K, Bögeman M, Yordanova A, Eveslage M, Schäfers M, Essler M, Ahmadzadehfar H.
Eur J Nucl Med Mol Imaging. 2018 Feb;45(2):243-246. doi: 10.1007/s00259-017-3877-z. Epub 2017 Nov 13.

 

 

6. Theranostics in nuclear medicine practice.

 

Yordanova A, Eppard E, Kürpig S, Bundschuh RA, Schönberger S, Gonzalez-Carmona M, Feldmann G, Ahmadzadehfar H, Essler M.
Onco Targets Ther. 2017 Oct 3;10:4821-4828. doi: 10.2147/OTT.S140671. eCollection 2017. Review.

 

 

7. Yttrium-90 radioembolization of unresectable hepatocellular carcinoma - a single center experience.
Meyer C, Pieper CC, Ahmadzadehfar H, Lampe NA, Matuschek EME, Maschke TA, Enkirch SJ, Essler M, Spengler U, Schild HH.
Onco Targets Ther. 2017 Sep 26;10:4773-4785. doi: 10.2147/OTT.S137519. eCollection 2017.

 

 

8. PSMA targeted radioligandtherapy in metastatic castration resistant prostate cancer after chemotherapy, abiraterone and/or enzalutamide. A retrospective analysis of overall survival.
Rahbar K, Boegemann M, Yordanova A, Eveslage M, Schäfers M, Essler M, Ahmadzadehfar H.
Eur J Nucl Med Mol Imaging. 2018 Jan;45(1):12-19. doi: 10.1007/s00259-017-3848-4. Epub 2017 Oct 12.

 

 

9. Radioligand therapy of metastatic prostate cancer using 177Lu-PSMA-617 after radiation exposure to 223Ra-dichloride.
Ahmadzadehfar H, Zimbelmann S, Yordanova A, Fimmers R, Kürpig S, Eppard E, Gaertner FC, Wei X, Hauser S, Essler M.
Oncotarget. 2017 Feb 25;8(33):55567-55574. doi: 10.18632/oncotarget.15698. eCollection 2017

 

 

10. Uptake of PSMA-ligands in normal tissues is dependent on tumor load in patients with prostate cancer.
Gaertner FC, Halabi K, Ahmadzadehfar H, Kürpig S, Eppard E, Kotsikopoulos C, Liakos N, Bundschuh RA, Strunk H, Essler M.
Oncotarget. 2017 Jul 6;8(33):55094-55103. doi: 10.18632/oncotarget.19049. eCollection 2017 Aug 15.

 

 

11. Improving quality of life in patients with pancreatic neuroendocrine tumor following peptide receptor radionuclide therapy assessed by EORTC QLQ-C30.
Marinova M, Mücke M, Mahlberg L, Essler M, Cuhls H, Radbruch L, Conrad R, Ahmadzadehfar H.
Eur J Nucl Med Mol Imaging. 2018 Jan;45(1):38-46. doi: 10.1007/s00259-017-3816-z. Epub 2017 Sep 1.

 

 

12. Comprehensive Evaluation of Prostate Specific Membrane Antigen Expression in the Vasculature of Renal Tumors: Implications for Imaging Studies and Prognostic Role.
Spatz S, Tolkach Y, Jung K, Stephan C, Busch J, Ralla B, Rabien A, Feldmann G, Brossart P, Bundschuh RA, Ahmadzadehfar H, Essler M, Toma M, Müller SC, Ellinger J, Hauser S, Kristiansen G.
J Urol. 2017 Aug 19. pii: S0022-5347(17)77376-4. doi: 10.1016/j.juro.2017.08.079. [Epub ahead of print]

 

 

13. Assessment of Bone Metastases in Patients with Prostate Cancer-A Comparison between 99mTc-Bone-Scintigraphy and [68Ga]Ga-PSMA PET/CT.
Thomas L, Balmus C, Ahmadzadehfar H, Essler M, Strunk H, Bundschuh RA.
Pharmaceuticals (Basel). 2017 Jul 31;10(3). pii: E68. doi: 10.3390/ph10030068.

 

 

14. Combination of 177Lu-PSMA-617 and External Radiotherapy for the Treatment of Cerebral Metastases in Patients With Castration-Resistant Metastatic Prostate Cancer.
Wei X, Schlenkhoff C, Schwarz B, Essler M, Ahmadzadehfar H.
Clin Nucl Med. 2017 Sep;42(9):704-706. doi: 10.1097/RLU.0000000000001763.

 

 

15. Possible Treatment Approach to an Extravasation of 177Lu-PSMA-617.
Schlenkhoff CD, Essler M, Ahmadzadehfar H.
Clin Nucl Med. 2017 Aug;42(8):639-640. doi: 10.1097/RLU.0000000000001715.

 

 

16. Overall survival and response pattern of castration-resistant metastatic prostate cancer to multiple cycles of radioligand therapy using [177Lu]Lu-PSMA-617.
Ahmadzadehfar H, Wegen S, Yordanova A, Fimmers R, Kürpig S, Eppard E, Wei X, Schlenkhoff C, Hauser S, Essler M.
Eur J Nucl Med Mol Imaging. 2017 Aug;44(9):1448-1454. doi: 10.1007/s00259-017-3716-2. Epub 2017 May 9.

 

 

17. [PET-CT in head and neck cancer].
Send T, Kreppel B, Gaertner FC, Bundschuh RA, Strunk H, Bootz F, Essler M.
HNO. 2017 Jun;65(6):504-513. doi: 10.1007/s00106-017-0355-7.
German.

 

 

18. The impact of repeated cycles of radioligand therapy using [177Lu]Lu-PSMA-617 on renal function in patients with hormone refractory metastatic prostate cancer.

 

Yordanova A, Becker A, Eppard E, Kürpig S, Fisang C, Feldmann G, Essler M, Ahmadzadehfar H.
Eur J Nucl Med Mol Imaging. 2017 Aug;44(9):1473-1479. doi: 10.1007/s00259-017-3681-9. Epub 2017 Mar 23.

 

 

19. Safety of multiple repeated cycles of 177Lu-octreotate in patients with recurrent neuroendocrine tumour.
Yordanova A, Mayer K, Brossart P, Gonzalez-Carmona MA, Strassburg CP, Essler M, Ahmadzadehfar H.
Eur J Nucl Med Mol Imaging. 2017 Jul;44(7):1207-1214. doi: 10.1007/s00259-017-3652-1. Epub 2017 Mar 1.

 

 

20. [18F]Fluorodeoxyglucose Positron Emission Tomography Reveals a Complete Remission of Refractory Metastatic Melanoma after Therapy with Ipilimumab.
Yordanova A, Schlenkhoff C, Palmedo H, Essler M, Ahmadzadehfar H.
Indian J Nucl Med. 2017 Jan-Mar;32(1):66-67. doi: 10.4103/0972-3919.198490.

 

 

21. α- Versus β-Emitting Radionuclides for Pretargeted Radioimmunotherapy of Carcinoembryonic Antigen-Expressing Human Colon Cancer Xenografts.
Heskamp S, Hernandez R, Molkenboer-Kuenen JDM, Essler M, Bruchertseifer F, Morgenstern A, Steenbergen EJ, Cai W, Seidl C, McBride WJ, Goldenberg DM, Boerman OC.

 

22. 18F-fluoroethyl-L-tyrosine positron emission tomography-guided diagnosis of a malignant intramedullary spinal cord tumor.
Kebir S, Kimmich O, Niehusmann P, Gaertner FC, Essler M, Landsberg J, Klockgether T, Simon M, Herrlinger U, Glas M.
Oncol Lett. 2016 Dec;12(6):4705-4707. doi: 10.3892/ol.2016.5234. Epub 2016 Oct 10.

 

 

23. A Step-by-Step Clinical Approach for the Management of Neuroendocrine Tumours.
Yordanova A, Ahmadzadehfar H, Gonzalez-Carmona M, Strassburg C, Mayer K, Feldmann G, Schmidt-Wolf I, Lingohr P, Fischer S, Kristiansen G, Essler M.
Horm Metab Res. 2017 Feb;49(2):77-85. doi: 10.1055/s-0042-121894. Epub 2017 Jan 18. Review.

 

 

24. Optimization of Labeling PSMAHBED with Ethanol-Postprocessed 68Ga and Its Quality Control Systems.
Eppard E, Homann T, de la Fuente A, Essler M, Rösch F.
J Nucl Med. 2017 Mar;58(3):432-437. doi: 10.2967/jnumed.116.177634. Epub 2017 Jan 12.

 

 

25.Unsupervised consensus cluster analysis of [18F]-fluoroethyl-L-tyrosine positron emission tomography identified textural features for the diagnosis of pseudoprogression in high-grade glioma.
Kebir S, Khurshid Z, Gaertner FC, Essler M, Hattingen E, Fimmers R, Scheffler B, Herrlinger U, Bundschuh RA, Glas M.
Oncotarget. 2017 Jan 31;8(5):8294-8304. doi: 10.18632/oncotarget.14166.

 

 

26.German Multicenter Study Investigating 177Lu-PSMA-617 Radioligand Therapy in Advanced Prostate Cancer Patients.
Rahbar K, Ahmadzadehfar H, Kratochwil C, Haberkorn U, Schäfers M, Essler M, Baum RP, Kulkarni HR, Schmidt M, Drzezga A, Bartenstein P, Pfestroff A, Luster M, Lützen U, Marx M, Prasad V, Brenner W, Heinzel A, Mottaghy FM, Ruf J, Meyer PT, Heuschkel M, Eveslage M, Bögemann M, Fendler WP, Krause BJ.
J Nucl Med. 2017 Jan;58(1):85-90. doi: 10.2967/jnumed.116.183194. Epub 2016 Oct 20.

 

 

27. Successful Repeated Peptide Receptor Radionuclide Therapies in Renal Neuroendocrine Tumor With Osseous Metastasis.
Yordanova A, Mayer K, Essler M, Ahmadzadehfar H.
Clin Nucl Med. 2016 Dec;41(12):977-979.

 

28. Successful Treatment of Hepatic Metastases of Hormone Refractory Prostate Cancer Using Radioligand Therapy With 177Lu-PSMA-617.

Wei X, Schlenkhoff C, Sopora C, Essler M, Ahmadzadehfar H.

Clin Nucl Med. 2016 Nov;41(11):894-895.

 

29.Survival prediction in patients undergoing radionuclide therapy based on intratumoral somatostatin-receptor heterogeneity.

Werner RA, Lapa C, Ilhan H, Higuchi T, Buck AK, Lehner S, Bartenstein P, Bengel F, Schatka I, Muegge DO, Papp L, Zsótér N, Große-Ophoff T, Essler M, Bundschuh RA.

Oncotarget. 2017 Jan 24;8(4):7039-7049. doi: 10.18632/oncotarget.12402.

 

30. 68Ga-PSMA-11 PET as a Gatekeeper for the Treatment of Metastatic Prostate Cancer with 223Ra: Proof of Concept.

Ahmadzadehfar H, Azgomi K, Hauser S, Wei X, Yordanova A, Gaertner FC, Kürpig S, Strunk H, Essler M.

J Nucl Med. 2017 Mar;58(3):438-444. doi: 10.2967/jnumed.116.178533. Epub 2016 Sep 22.

 

31. Predictors of Response to Radioligand Therapy of Metastatic Castrate-Resistant Prostate Cancer with 177Lu-PSMA-617.

Ferdinandus J, Eppard E, Gaertner FC, Kürpig S, Fimmers R, Yordanova A, Hauser S, Feldmann G, Essler M, Ahmadzadehfar H.

J Nucl Med. 2017 Feb;58(2):312-319. doi: 10.2967/jnumed.116.178228. Epub 2016 Sep 1.

Dr. med. Florian Gärtner

 

1. Mol Imaging Biol. 2017 Feb;19(1):120-129. doi: 10.1007/s11307-016-0975-4.

Quantitative Analysis of [18F]FMISO PET for Tumor Hypoxia: Correlation of Modeling Results with Immunohistochemistry.

Shi K, Bayer C, Astner ST, Gaertner FC, Vaupel P, Schwaiger M, Huang SC, Ziegler SI.

 

2. J Nucl Med. 2017 Feb;58(2):312-319. doi: 10.2967/jnumed.116.178228. Epub 2016 Sep 1.

Predictors of Response to Radioligand Therapy of Metastatic Castrate-Resistant Prostate Cancer with 177Lu-PSMA-617.

Ferdinandus J, Eppard E, Gaertner FC, Kürpig S, Fimmers R, Yordanova A, Hauser S, Feldmann G, Essler M, Ahmadzadehfar H.

 

3. J Nucl Med. 2017 Mar;58(3):438-444. doi: 10.2967/jnumed.116.178533. Epub 2016 Sep 22.

68Ga-PSMA-11 PET as a Gatekeeper for the Treatment of Metastatic Prostate Cancer with 223Ra: Proof of Concept.

Ahmadzadehfar H, Azgomi K, Hauser S, Wei X, Yordanova A, Gaertner FC, Kürpig S, Strunk H, Essler M.

 

4. Thorax. 2017 Mar;72(3):286-287. doi: 10.1136/thoraxjnl-2016-208834. Epub 2016 Dec 5.

Prevention of sudden cardiac death by the wearable cardioverter defibrillator in a young patient with cardiac sarcoidosis.

Andrié R, Gaertner FC, Skowasch D.

 

5. Physiol Meas. 2017 Feb;38(2):188-204. doi: 10.1088/1361-6579/aa5071. Epub 2017 Jan 5.

Matching the reaction-diffusion simulation to dynamic [18F]FMISO PET measurements in tumors: extension to a flow-limited oxygen-dependent model.

Shi K, Bayer C, Gaertner FC, Astner ST, Wilkens JJ, Nüsslin F, Vaupel P, Ziegler SI.

 

6. Oncotarget. 2017 Jan 31;8(5):8294-8304. doi: 10.18632/oncotarget.14166.

Unsupervised consensus cluster analysis of [18F]-fluoroethyl-L-tyrosine positron emission tomography identified textural features for the diagnosis of pseudoprogression in high-grade glioma.

Kebir S, Khurshid Z, Gaertner FC, Essler M, Hattingen E, Fimmers R, Scheffler B, Herrlinger U, Bundschuh RA, Glas M

 

7. Parkinsonism Relat Disord. 2017 Apr;37:111-113. doi: 10.1016/j.parkreldis.2017.01.005. Epub 2017 Jan 10.

Expanded phenotype and hippocampal involvement in a novel compound heterozygosity of adult PLA2G6 associated neurodegeneration (PARK14).

Michelis JP, Hattingen E, Gaertner FC, Minnerop M, Träber F, Biskup S, Klockgether T, Paus S.

 

8. Oncotarget. 2017 Feb 25;8(33):55567-55574. doi: 10.18632/oncotarget.15698. eCollection 2017 Aug 15.

Radioligand therapy of metastatic prostate cancer using 177Lu-PSMA-617 after radiation exposure to 223Ra-dichloride.

Ahmadzadehfar H, Zimbelmann S, Yordanova A, Fimmers R, Kürpig S, Eppard E, Gaertner FC, Wei X, Hauser S, Essler M.

 

9. HNO. 2017 Jun;65(6):504-513. doi: 10.1007/s00106-017-0355-7.

[PET-CT in head and neck cancer].

[Article in German]

Send T, Kreppel B, Gaertner FC, Bundschuh RA, Strunk H, Bootz F, Essler M.

 

10. Oncotarget. 2017 Jul 6;8(33):55094-55103. doi: 10.18632/oncotarget.19049. eCollection 2017 Aug 15.

Uptake of PSMA-ligands in normal tissues is dependent on tumor load in patients with prostate cancer.

Gaertner FC, Halabi K, Ahmadzadehfar H, Kürpig S, Eppard E, Kotsikopoulos C, Liakos N, Bundschuh RA, Strunk H, Essler M.

 

11. ESC Heart Fail. 2017 Dec 12. doi: 10.1002/ehf2.12243. [Epub ahead of print]

Cardiovascular magnetic resonance imaging and clinical performance of somatostatin receptor positron emission tomography in cardiac sarcoidosis.

Pizarro C, Kluenker F, Dabir D, Thomas D, Gaertner FC, Essler M, Grohé C, Nickenig G, Skowasch D.

 

12. Oncotarget. 2017 Oct 7;8(61):103108-103116. doi: 10.18632/oncotarget.21600. eCollection 2017 Nov 28.

Predictors of overall survival in metastatic castration-resistant prostate cancer patients receiving [177Lu]Lu-PSMA-617 radioligand therapy.

Ahmadzadehfar H, Schlolaut S, Fimmers R, Yordanova A, Hirzebruch S, Schlenkhoff C, Gaertner FC, Awang ZH, Hauser S, Essler M.

 

Priv.-Doz. Dr. med. Hojjat Ahmad-Zadehfar, MSc

Originalarbeiten

Erstautorenschaften:

1. Ahmadzadehfar H, Schlolaut S, Fimmers R, Yordanova A, Hirzebruch S, Schlenkhoff C, Gaertner FC, Awang ZH, Hauser S, Essler M. Predictors of overall survival in metastatic castration-resistant prostate cancer patients receiving [177Lu]Lu-PSMA-617 radioligand therapy. Oncotarget 2017

2. Ahmadzadehfar H, Aryana K, Farzanehfar S, Pirayesh E, Assadi M, Fallahi B, Shafiei B, Ayati N, Amoui M. The Iranian society of Nuclear Medicine practical guideline on radioligand therapy (RLT) in metastatic castration-resistant prostate cancer using 177Lu-PSMA V.1.0. Iranian Journal of Nuclear Medicine 2018. angenommen

3. Ahmadzadehfar H, Zimbelmann S, Yordanova S, Fimmers R, Kürpig S, Eppard E, Gaertner FC, Wei X, Hauser S, Essler M. Radioligand therapy of metastatic prostate cancer using 177Lu-PSMA-617 after radiation exposure to 223Ra-dichloride. Oncotarget. 2017 Feb 25;8(33):55567-55574.

4. Ahmadzadehfar H, Azgomi K, Hauser S, Wei X, Yordanova A, Gaertner F, Kürpig S, Strunk H, Essler M. 68Ga-PSMA-11 PET as a gate-keeper for the treatment of metastatic prostate cancer with radium-223: proof of concept. J Nucl Med. 2017 Mar;58(3):438-444.

5. Rahbar K, Ahmadzadehfar H, Kratochwil C, Haberkorn U, Schäfers M, Essler M, Baum RP, Kulkarani HR, Schmidt M, Bartenstein P, Pfestroff A, Lützen U, Marx M, Prasad V, Brenner W, Heinzel A, Ruf J, Meyer PT, Heuschkel M, Eveslage M, Bögemann M, Fendler WP, Krause BJ. German multicenter study investigating 177Lu-PSMA-617 radioligand therapy in advanced prostate cancer patients. J Nucl Med. 2017 Jan;58(1):85-90.

6. Ahmadzadehfar H, Wegen S, Yordanova A, Fimmers R, Kürpig S, Eppard E, Wei X, Schlenkhoff C, Hauser S, Essler M. Overall survival and response pattern of castration-resistant metastatic prostate cancer to multiple cycles of radioligand therapy using [177Lu]Lu-PSMA-617.Eur J Nucl Med Mol Imaging. 2017 Aug;44(9):1448-1454.

 

Letztautorenschaften:

1. Rahbar K, Bögeman M, Yordanova A, Eveslage M, Schäfers M, Essler M and Ahmadzadehfar H. Delayed response after repeated 177Lu-PSMA-617 radioligand therapy in patients with metastatic castration resistant prostate cancer. EJNMMI 2017 angenommen

 

2.Yordanova A, Mahjoob S, Lingohr P, Kalf J, Türler A, Palmedo H, Biersack HJ, Kristiansen G, Farahati J, Essler M, Ahmadzadehfar H.Diagnostic accuracy of [99mTc]Tc-Sestamibi in the assessment of thyroid nodules. Oncotarget 2017. 8 (55):94681 - 94691

 

3. Rahbar K, Boegemann M, Yordanova A, Eveslage M, Schäfers M, Essler M, Ahmadzadehfar H. PSMA targeted radioligandtherapy in metastatic castration resistant prostate cancer after chemotherapy, abiraterone and/or enzalutamide. A retrospective analysis of overall survival.Eur J Nucl Med Mol Imaging. 2017 Oct 12.

 

4. Marinova M, Mücke M, Mahlberg L, Essler M, Cuhls H, Radbruch L, Conrad R, Ahmadzadehfar H.Improving quality of life in patients with pancreatic neuroendocrine tumor following peptide receptor radionuclide therapy assessed by EORTC QLQ-C30.Eur J Nucl Med Mol Imaging. 2017 Sep 1.

 

5. Yordanova A, Becker A, Eppard E, Kürpig S, Fisang C, Feldmann G, Essler M, Ahmadzadehfar H. The impact of repeated cycles of radioligand therapy using [177Lu]Lu-PSMA-617 on renal function in patients with hormone refractory metastatic prostate cancer. Eur J Nucl Med Mol Imaging. 2017 Aug 44(9):1473-1479.

 

6.Yordanova A, Mayer K, Brossart P, Gonzalez-Carmona MA, Strassburg CP, Essler M, Ahmadzadehfar H. Safety of multiple repeated cycles of 177Lu-octreotate in patients with recurrent neuroendocrine tumour. Eur J Nucl Med Mol Imaging. 2017 Jul;44(7):1207-1214.

 

7. Ferdinandus J, Eppard E, Gaertner F, Kürpig S, Fimmers R, Yordanova A, Hauser S, Feldmann G, Essler E, Ahmadzadehfar H. Predictors of response to radioligand therapy of metastatic castrate-resistant prostate cancer with 177Lu-PSMA-617. J Nucl Med. 2017 Feb;58(2):312-319

 

Co-Autorenschaften

 

1. Meyer C, Pieper CC, Ahmadzadehfar H, Lampe NA, Matuschek EME, Maschke TA, Enkirch SJ, Essler M, Spengler U, Schild HH.Yttrium-90 radioembolization of unresectable hepatocellular carcinoma - a single center experience.Onco Targets Ther. 2017 Sep 26;10:4773-4785. doi: 10.2147/OTT.S137519.

 

2. Gaertner FC, Halabi K, Ahmadzadehfar H, Kürpig S, Eppard E, Kotsikopoulos C, Liakos N, Bundschuh RA, Strunk H, Essler M. Uptake of PSMA-ligands in normal tissues is dependent on tumor load in patients with prostate cancer.Oncotarget. 2017 Jul 6;8(33):55094-55103. doi: 10.18632/oncotarget.19049.

 

3. Spatz S, Tolkach Y, Jung K, Stephan C, Busch J, Ralla B, Rabien A, Feldmann G, Brossart P, Bundschuh RA, Ahmadzadehfar H, Essler M, Toma M, Müller SC, Ellinger J, Hauser S, Kristiansen G. Comprehensive Evaluation of Prostate-Specific Membrane Antigen Expression in the Vasculature of Renal Tumors: Implications for Imaging Studies and Prognostic Role.J Urol. 2017 Aug 18. pii: S0022-5347(17)77376-4. doi: 10.1016/j.juro.2017.08.079.

 

4. Thomas L, Balmus C, Ahmadzadehfar H, Essler M, Strunk H, Bundschuh RA.Assessment of Bone Metastases in Patients with Prostate Cancer-A Comparison between 99mTc-Bone-Scintigraphy and [68Ga]Ga-PSMA PET/CT. Pharmaceuticals (Basel). 2017 Jul 31;10(3). pii: E68. doi: 10.3390/ph10030068.

 

5. Murtz P, Kaschner MG, Hinterthaner B, Simon B, Ahmadzadehfar H, Skowasch D, Schild HH, Willinek WA, Kukuk GM. Diffusion-weighted Whole-body MRI at 3 Tesla for the Detection and Discrimination of Pulmonary Tumors. (2017) J Imaging Sci 2(1): 1- 8.

 

6. Samim M, van Veenendaal LM, Braat A, van den Hoven A, Hillegersberg R, Sangro B, Kao Y, Liu D, Louie J , Sze D, Rose S, Brown D, Ahmadzadehfar H, Kim E, van den Bosch M, Lam M. Recommendations for radioembolization after liver surgery using yttrium-90 resin microspheres: an international consensus panel report. Eur Radiol. 2017 Jul 3. doi: 10.1007/s00330-017-4889-6.

 

Übersichtsartikel

 

1. Yordanova A, Eppard E, Kürpig S, Bundschuh RA, Schönberger S, Gonzalez-Carmona M, Feldmann G, Ahmadzadehfar H, Essler M.Theranostics in nuclear medicine practice. Onco Targets Ther. 2017 Oct 3;10:4821-4828. doi: 10.2147/OTT.S140671.

 

2. Yordanova A, Ahmadzadehfar H, Gonzalez-Carmona M, Strassburg C, Mayer K, Feldmann G, Schmidt-Wolf I, Lingohr P, Fischer S, Kristiansen G, Essler M. A Step-by-Step Clinical Approach for the Management of Neuroendocrine Tumours. Horm Metab Res. 2017 Feb;49(2):77-85.

 

Kasuistiken und Letters

 

1. Rahbar K, Ahmadzadehfar H, Boegemann M. 177Lu-PSMA-617 radioligand therapy in mCRPC: ready for phase III trial? Eur J Nucl Med Mol Imaging. 2017 Nov 21.

 

2. Wei X, Schlenkhoff C, Schwarz B, Essler M, Ahmadzadehfar H.Combination of 177Lu-PSMA-617 and External Radiotherapy for the Treatment of Cerebral Metastases in Patients With Castration-Resistant Metastatic Prostate Cancer.Clin Nucl Med. 2017 Sep;42(9):704-706.

 

3. Schlenkhoff CD, Essler M, Ahmadzadehfar H. Possible Treatment Approach to an Extravasation of 177Lu-PSMA-617. Clin Nucl Med. 2017 Aug;42(8):639-640.

 

4. Yordanova A, Schlenkhoff C, Palmedo H, Essler M, Ahmadzadehfar H. [18F]Fluorodeoxyglucose Positron Emission Tomography Reveals a Complete Remission of Refractory Metastatic Melanoma after Therapy with Ipilimumab.

Indian J Nucl Med. 2017 Jan-Mar;32(1):66-67.

 

5. Rahbar K, Bögemann M, Ahmadzadehfar H. 177Lu-PSMA-617 radioligand therapy of mCRPC: evaluation criteria of response. Eur J Nucl Med Mol Imaging. 2017 Jan;44(1):166-167.

 

Professor Dr. rer. nat. Dr. med. Ralph A. Bundschuh

 

1. E. Eppard, A. de la Fuente, A. Benesova, A. Khawar, R. A. Bundschuh, F. C. Gärtner, B. Kreppel, K. Kopka, M. Essler, F. Rösch: Clinical Translation and First In-Human Use of [44Sc]Sc-PSMA-617 for PET Imaging of Metastasized Castrate-Resistant Prostate Cancer. Theranostics, 7(18):4359-4369, 2017. (IF 8,766)

 

2. S. Spatz, Y. Tolkach, K. Jung, C. Stephan, J. Busch, B. Ralla, A. Rabien, G. Feldmann, P. Brossart, R. A. Bundschuh, H. Ahmadzadefar, M. Essler, M. Toma, S. C. Müller, J. Ellinger, S. Hauser, G. Kristiansen: Comprehensive Evaluation of Prostate-Specific Membran Antigen Expression in the Vasculature of Renal Tumors: Implication for Imaging Studies and Prognostic Role. J. Urol., 2017 [Epub ahead of print]. (IF 5,157)

 

3. L. Thomas, C. Balmus, H. Ahmadzadehfar, M. Essler, H. Strunk, R. A. Bundschuh: Assessment of Bone Metastases in Patients with Prostate Cancer – A Comparison between 99mTc-Bone-Scintigraphy and [68Ga]Ga-PSMA PET/CT. Pharmaceuticals, 10(3), 2017. (IF 5,30)

 

4. F. C. Gaertner, K. Halabi, H. Ahmadzadehfar, S. Kürpig, E. Eppard, C. Kotsikopoulos, N. Liakos, R. A. Bundschuh, H. Strunk, M. Essler: Uptake of PSMA-ligands in normal tissue is dependent on Tumor Load in Patients with Prostate Cancer. Oncotarget, 8(33):55094-55103, 2017. (IF 5,168)

 

5. S. Kebir, Z. Kurshid, F. C. Gaertner, M. Essler, E. Hattingen, R. Fimmers, B. Scheffler, U. Herrlinger, R. A. Bundschuh*, M. Glas*: Unsupervised Consensus Cluster Analysis of [18F]-fluorethyl-L-tyrosine Positron Emission Tomography Identified Textural Features for the Diagnosis of Pseudoprogression in High-Grade Glioma. Oncotarget, 8(5): 8294-8304, 2017. (IF 5,168)

*both authors contributed in equal to the manuscript

 

Dr. med. Carl Schlenkhoff

 

Ahmadzadehfar H, Schlolaut S, Fimmers R, Yordanova A, Hirzebruch S, Schlenkhoff C, Gaertner FC, Awang ZH, Hauser S, Essler M.; Predictors of overall survival in metastatic castration-resistant prostate cancer patients receiving [177Lu]Lu-PSMA-617 radioligand therapy; Oncotarget. 2017 Oct 7;8(61):103108-103116. doi: 10.18632/oncotarget.21600 . eCollection 2017 Nov 28.

 

Wei X, Schlenkhoff C, Schwarz B, Essler M, Ahmadzadehfar H.; Combination of 177Lu-PSMA-617 and External Radiotherapy for the Treatment of Cerebral Metastases in Patients With Castration-Resistant Metastatic Prostate Cancer; Clin Nucl Med. 2017 Sep;42(9):704-706. doi: 10.1097/RLU.0000000000001763 .

 

Schlenkhoff CD, Essler M, Ahmadzadehfar H.; Possible Treatment Approach to an Extravasation of 177Lu-PSMA-617; Clin Nucl Med. 2017 Aug;42(8):639-640. doi: 10.1097/RLU.0000000000001715 .

 

Ahmadzadehfar H, Wegen S, Yordanova A, Fimmers R, Kürpig S, Eppard E, Wei X, Schlenkhoff C, Hauser S, Essler M.; Overall survival and response pattern of castration-resistant metastatic prostate cancer to multiple cycles of radioligand therapy using [177Lu]Lu-PSMA-617; Eur J Nucl Med Mol Imaging. 2017 Aug;44(9):1448-1454. doi: 10.1007/s00259-017-3716-2 . Epub 2017 May 9.

 

Yordanova A, Schlenkhoff C, Palmedo H, Essler M, Ahmadzadehfar H.; [18F]Fluorodeoxyglucose Positron Emission Tomography Reveals a Complete Remission of Refractory Metastatic Melanoma after Therapy with Ipilimumab. Indian J Nucl Med. 2017 Jan-Mar;32(1):66-67. doi: 10.4103/0972-3919.198490 .

 

 Nicht Medline gelistet:

 

Schlenkhoff C, Wie X, Gaertner FC, Essler M; Nuklearkardiologie: Methodik und klinischeWertigkeit; Herzmedizin 06/17

 

Dr. med. Bettina Schwarz

Combination of 177Lu-PSMA-617 and External Radiotherapy for the Treatment of Cerebral Metastases in Patients With Castration-Resistant Metastatic Prostate Cancer.

Wei X1, Schlenkhoff C, Schwarz B, Essler M, Ahmadzadehfar H.

Author information

1. From the Department of Nuclear Medicine, University Hospital Bonn, Bonn, Germany.

Dr. med. Anna Yordanova

 

[1] Ahmadzadehfar H, Zimbelmann S, Yordanova A, Fimmers R, Kurpig S, Eppard E et al. Radioligand therapy of metastatic prostate cancer using 177Lu-PSMA-617 after radiation exposure to 223Ra-dichloride. Oncotarget 2017.

 

[2] Ferdinandus J, Eppard E, Gaertner FC, Kurpig S, Fimmers R, Yordanova A et al. Predictors of Response to Radioligand Therapy of Metastatic Castrate-Resistant Prostate Cancer with 177Lu-PSMA-617. J Nucl Med 2017;58(2):312–9.

 

[3] Rahbar K, Braeuer A, Yordanova A, Boegemann M, Hauser S, Eveslage M et al. Antitumor activity of repeated 177Lu-PSMA-617 radioligand therapy in patients with metastatic castration resistant prostate cancer. Journal of Nuclear Medicine 2017;58(supplement 1):315.

 

[4] Rahbar K, Bögeman M, Yordanova A, Eveslage M, Schäfers M, Essler M et al. Delayed response after repeated 177 Lu-PSMA-617 radioligand therapy in patients with metastatic castration resistant prostate cancer. European Journal of Nuclear Medicine and Molecular Imaging 2017:1–4.

 

[5] Yordanova A, Schlenkhoff C, Palmedo H, Essler M, Ahmadzadehfar H. 18FFluorodeoxyglucose Positron Emission Tomography Reveals a Complete Remission of Refractory Metastatic Melanoma after Therapy with Ipilimumab. Indian J Nucl Med 2017;32(1):66–7.

 

[6] Yordanova A, Ahmadzadehfar H, Gonzalez-Carmona M, Strassburg C, Mayer K, Feldmann G et al. A Step-by-Step Clinical Approach for the Management of Neuroendocrine Tumours. Horm Metab Res 2017;49(2):77–85.

 

[7] Yordanova A, Mahjoob S, Lingohr P, Kalff J, Türler A, Palmedo H et al. Diagnostic accuracy of [99mTc] Tc-Sestamibi in the assessment of thyroid nodules. Oncotarget 2017;8(55):94681.

 

[8] Yordanova A, Mayer K, Brossart P, Gonzalez-Carmona MA, Strassburg CP, Essler M et al. Safety of multiple repeated cycles of 177Lu-octreotate in patients with recurrent neuroendocrine tumour. European Journal of Nuclear Medicine and Molecular Imaging 2017.

 

[9] Yordanova A, Becker A, Eppard E, Kurpig S, Fisang C, Feldmann G et al. The impact of repeated cycles of radioligand therapy using 177LuLu-PSMA-617 on renal function in patients with hormone refractory metastatic prostate cancer. European Journal of Nuclear Medicine and Molecular Imaging 2017.

 

[10] Yordanova A, Eppard E, Kürpig S, Bundschuh RA, Schönberger S, Gonzalez-Carmona M et al. Theranostics in nuclear medicine practice. OncoTargets and therapy 2017;10:4821.

 

[11] Ahmadzadehfar H, Azgomi K, Hauser S, Wei X, Yordanova A, Gaertner FC et al. 68Ga-PSMA-11 PET as a Gatekeeper for the Treatment of Metastatic Prostate Cancer with 223Ra: Proof of Concept. Journal of Nuclear Medicine 2017;58(3):438–44.

 

[12] Ahmadzadehfar H, Azgomi K, Hauser S, Wei X, Yordanova A, Gaertner FC et al. 68Ga-PSMA-11 PET as a Gatekeeper for the Treatment of Metastatic Prostate Cancer with 223Ra: Proof of Concept. J Nucl Med 2017;58(3):438–44.

 

[13] Ahmadzadehfar H, Wegen S, Yordanova A, Fimmers R, Kurpig S, Eppard E et al. Overall survival and response pattern of castration-resistant metastatic prostate cancer to multiple cycles of radioligand therapy using 177LuLu-PSMA-617. European Journal of Nuclear Medicine and Molecular Imaging 2017.

 

[14] Ahmadzadehfar H, Schlolaut S, Fimmers R, Yordanova A, Hirzebruch S, Schlenkhoff C et al. Predictors of overall survival in metastatic castration-resistant prostate cancer patients receiving [177Lu] Lu-PSMA-617 radioligand therapy. Oncotarget 2017;8(61):103108.

 

Dr. med. Barbara Schmidt-Kreppel

 

[PET-CT in head and neck cancer].

Send T, Kreppel B, Gaertner FC, Bundschuh RA, Strunk H, Bootz F, Essler M.

HNO. 2017

 

Clinical Translation and First In-Human Use of [44Sc]Sc-PSMA-617 for PET Imaging of Metastasized Castrate-Resistant Prostate Cancer.

 

Eppard E, de la Fuente A, Benešová M, Khawar A, Bundschuh RA, Gärtner FC, Kreppel B, Kopka K, Essler M, Rösch F.

 

Theranostics. 2017 Sep 26;7(18):4359-4369. doi: 10.7150/thno.20586. eCollection 2017.

 

PET/CT surveillance versus neck dissection in advanced head and neck cancer.

 Kreppel M, Kreppel B, Zöller JE.

 

Oral Dis. 2017 May;23(4):409-411. doi: 10.1111/odi.12538. Epub 2016 Aug 1.

 

Dr. rer. nat. Stefan Hirzebruch

 

Oncotarget. 2017 Oct 7;8(61):103108-103116. doi: 10.18632/oncotarget.21600. eCollection 2017 Nov 28.

Predictors of overall survival in metastatic castration-resistant prostate cancer patients receiving [177Lu]Lu-PSMA-617 radioligand therapy.

Ahmadzadehfar H1, Schlolaut S1, Fimmers R2, Yordanova A1, Hirzebruch S1, Schlenkhoff C1, Gaertner FC1, Awang ZH1, Hauser S3, Essler M1.

Dr. med. Xiao Wei

 

1. Radioligand therapy of metastatic prostate cancer using 177Lu-PSMA-617 after radiation exposure to 223Ra-dichloride.

Ahmadzadehfar H, Zimbelmann S, Yordanova A, Fimmers R, Kürpig S, Eppard E, Gaertner FC, Wei X, Hauser S, Essler M.

 

2. Combination of 177Lu-PSMA-617 and External Radiotherapy for the Treatment of Cerebral Metastases in Patients With Castration-Resistant Metastatic Prostate Cancer.

Wei X, Schlenkhoff C, Schwarz B, Essler M, Ahmadzadehfar H.

 

3. Overall survival and response pattern of castration-resistant metastatic prostate cancer to multiple cycles of radioligand therapy using [177Lu]Lu-PSMA-617.

Ahmadzadehfar H, Wegen S, Yordanova A, Fimmers R, Kürpig S, Eppard E, Wei X, Schlenkhoff C, Hauser S, Essler M.

 

4. 68Ga-PSMA-11 PET as a Gatekeeper for the Treatment of Metastatic Prostate Cancer with 223Ra: Proof of Concept.

Ahmadzadehfar H, Azgomi K, Hauser S, Wei X, Yordanova A, Gaertner FC, Kürpig S, Strunk H, Essler M.

 

Terminvergabe

Bitte vereinbaren Sie telefonisch einen Termin.

Schilddrüsenambulanz:
Tel.: +49 (0) 228 / 287-16171

Fax: +49 (0) 228 / 287-16615

PET/CT:
Tel.: +49 (0) 228 / 287 - 11088
Fax: +49 (0) 228 / 287-16207

Konventionelle Szintigraphie:
Tel.: +49 (0) 228 / 287-16171

Therapie-Sekretariat:
Tel.: +49 (0) 228 / 287-16974

Fax: +49 (0) 228 / 287-19057

Therapiestation Winkler:
Tel.: +49 (0) 228 / 287-16855
Fax: +49 (0) 228 / 287-19107

 

Befundabfrage:

Mo. - Do.: 08:00 Uhr - 16:00 Uhr

Fr.: 08:00 Uhr - 13:00 Uhr

Tel.: +49 (0)228 / 287 - 15181

Fax: +49 (0)228 / 287 - 19096

klinik.nuklearmedizin@ukbonn.de

 

 

Klinik und Poliklinik für Nuklearmedizin

Universitätsklinikum Bonn (AöR)

Sigmund-Freud-Straße 25

D-53127 Bonn